Norepinephrine + dopamine reuptake inhibitor with nicotinic-ACh-receptor antagonism (mechanism behind smoking-cessation indication). Active hydroxybupropion metabolite contributes. No sexual side effects and mild weight-neutral-to-loss profile → often chosen when SSRI sexual dysfunction is a problem.
Half-Life & Elimination Curve (PO: 14h)
Plasma (PO)t½ Decay (14h)
0×t½0h100%(6.65 µg/L)
1×t½14h50%(3.32 µg/L)
2×t½28h25%(1.66 µg/L)
3×t½42h12.5%(0.831 µg/L)
4×t½56h6.3%(0.415 µg/L)
5×t½70h3.1%(0.208 µg/L)
Elimination t½14h (PO)
Rate Constant (ke)0.0495 h⁻¹
Time to Peak (Tmax)5.13h
Est. Peak (Cmax)6.65 µg/L
Clearance (CL)86.6 L/h
97% Washout (5×t½)70h
Dosing Guidelines
Oral (PO): Typical 250 mg (Range: 150–450 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 6% · Volume of Distribution (Vd): 1750 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h) [PMID 27255113]